Literature DB >> 25432985

PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects.

Fernando Soler1, Francisco Fernández-Belda1, Joaquín Pérez-Schindler2, Christoph Handschin2, Teodomiro Fuente3, Jesús Hernandez-Cascales4.   

Abstract

The important regulator of cardiac function, cAMP, is hydrolyzed by different cyclic nucleotide phosphodiesterases (PDEs), whose expression and activity are not uniform throughout the heart. Of these enzymes, PDE2 shapes β1 adrenoceptor-dependent cardiac cAMP signaling, both in the right and left ventricular myocardium, but its role in regulating β2 adrenoceptor-mediated responses is less well known. Our aim was to investigate possible differences in PDE2 transcription and activity between right (RV) and left (LV) rat ventricular myocardium, as well as its role in regulating β2 adrenoceptor effects. The free walls of the RV and the LV were obtained from Sprague-Dawley rat hearts. Relative mRNA for PDE2 (quantified by qPCR) and PDE2 activity (evaluated by a colorimetric procedure and using the PDE2 inhibitor EHNA) were determined in RV and LV. Also, β2 adrenoceptor-mediated effects (β2-adrenoceptor agonist salbutamol + β1 adrenoceptor antagonist CGP-20712A) on contractility and cAMP concentrations, in the absence or presence of EHNA, were studied in the RV and LV. PDE2 transcript levels were less abundant in RV than in LV and the contribution of PDE2 to the total PDE activity was around 25% lower in the microsomal fraction of the RV compared with the LV. β2 adrenoceptor activation increased inotropy and cAMP levels in the LV when measured in the presence of EHNA, but no such effects were observed in the RV, either in the presence or absence of EHNA. These results indicate interventricular differences in PDE2 transcript and activity levels, which may distinctly regulate β2 adrenoceptor-mediated contractility and cAMP concentrations in the RV and in the LV of the rat heart.
© 2014 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  PDE2 activity; cAMP levels; inotropy; interventricular differences; β2 adrenoceptor

Mesh:

Substances:

Year:  2014        PMID: 25432985      PMCID: PMC4935361          DOI: 10.1177/1535370214560969

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  45 in total

1.  A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.

Authors:  Francesca Rochais; Aniella Abi-Gerges; Kathleen Horner; Florence Lefebvre; Dermot M F Cooper; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

2.  Cytoplasmic cAMP concentrations in intact cardiac myocytes.

Authors:  Radu V Iancu; Gopalakrishnan Ramamurthy; Sunita Warrier; Viacheslav O Nikolaev; Martin J Lohse; Stephen W Jones; Robert D Harvey
Journal:  Am J Physiol Cell Physiol       Date:  2008-06-11       Impact factor: 4.249

Review 3.  Relaxation and diastole of the heart.

Authors:  D L Brutsaert; S U Sys
Journal:  Physiol Rev       Date:  1989-10       Impact factor: 37.312

Review 4.  Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels.

Authors:  Rodolphe Fischmeister; Liliana Castro; Aniella Abi-Gerges; Francesca Rochais; Grégoire Vandecasteele
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2005-05-31       Impact factor: 2.320

5.  The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.

Authors:  María Jesús Juan-Fita; María Luisa Vargas; Jesús Hernández
Journal:  Eur J Pharmacol       Date:  2005-04-11       Impact factor: 4.432

6.  Proteomic analysis of right and left cardiac ventricles under aerobic conditions and after ischemia/reperfusion.

Authors:  Virgilio J J Cadete; Han-bin Lin; Jolanta Sawicka; Mieczyslaw Wozniak; Grzegorz Sawicki
Journal:  Proteomics       Date:  2012-08       Impact factor: 3.984

7.  Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase.

Authors:  H S Penefsky
Journal:  J Biol Chem       Date:  1977-05-10       Impact factor: 5.157

8.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway.

Authors:  V O Rybin; X Xu; M P Lisanti; S F Steinberg
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

9.  Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.

Authors:  E N Juberg; K P Minneman; P W Abel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-09       Impact factor: 3.000

10.  Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases.

Authors:  Marco Mongillo; Theresa McSorley; Sandrine Evellin; Arvind Sood; Valentina Lissandron; Anna Terrin; Elaine Huston; Annette Hannawacker; Martin J Lohse; Tullio Pozzan; Miles D Houslay; Manuela Zaccolo
Journal:  Circ Res       Date:  2004-06-03       Impact factor: 17.367

View more
  3 in total

1.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 2.  Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Authors:  Gaia Calamera; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 3.  An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Authors:  Si Chen; Chen Yan
Journal:  Expert Opin Drug Discov       Date:  2020-09-21       Impact factor: 6.098

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.